evipedia.ai
← Back

St. John's Wort for Health & Longevity

Evidence Review created on 09/27/2026 using AI4L / Opus 5.5

Also known as: Hypericum perforatum, Hypericum, Common St. John’s Wort, Perforate St. John’s Wort, SJW, Klamath Weed, Tipton’s Weed, Goatweed, Johanniskraut, Hyperici Herba

Motivation

St. John’s wort (Hypericum perforatum) is a yellow-flowering meadow plant whose standardized extracts are among the most studied herbal products for mood. It is of interest to health-focused adults because it offers a plant-based option for low mood and some menopausal complaints, while also carrying a reputation for serious clashes with prescription medications.

The herb has been used in European folk medicine for centuries and became a licensed treatment for low mood in Germany long before it turned into a best-selling supplement in the United States. Its main active compound appears to raise the availability of several mood-related brain messengers, yet the same compound also switches on the body’s drug-clearing machinery in the liver and gut. That dual character, together with trials that disagree with one another, keeps the herb at the center of debate.

This review examines what controlled studies show about its benefits for mood and related symptoms, how large and reliable those effects are, which risks and medication interactions matter most, and how the evidence applies to proactive adults pursuing long-term health.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and narrative reviews that give a high-level overview of St. John’s wort, its evidence base and its safety profile.

No directly relevant content on St. John’s wort was found from Rhonda Patrick (FoundMyFitness), Peter Attia, Andrew Huberman or Lifespan.io: their site searches returned no matching or only incidental results, and Huberman’s depression episode does not cover the herb.

Grokipedia

Hypericum perforatum

An AI-generated encyclopedia entry covering the plant’s botany, chemistry, pharmacology and traditional and modern uses; useful for background on constituents and history rather than for weighing clinical evidence.

Examine

St. John’s Wort

An evidence database page summarizing depression trials, the typical 900 mg daily dose, and a safety section on liver-enzyme drug interactions, pregnancy and product adulteration.

ConsumerLab

St. John’s Wort Supplements Review

Independent product testing found 60% of selected supplements fell short on key plant compounds, with hyperforin content varying up to 280-fold between products; full results require membership.

Systematic Reviews

This section lists the key systematic reviews and meta-analyses on St. John’s wort’s effectiveness for depression and on its adverse effects and drug interactions.

Mechanism of Action

The extracts contain hyperforin, the red pigments hypericin and pseudohypericin, and flavonoids.

  • Mood effects: Hyperforin inhibits the reuptake of serotonin, norepinephrine and dopamine, but indirectly. It opens TRPC6 (transient receptor potential canonical 6, a calcium and sodium channel on nerve cells), which disturbs the sodium gradient that reuptake pumps rely on (Leuner et al., 2007). Hypericin weakly inhibits MAO (monoamine oxidase, an enzyme that breaks down mood messengers) only at concentrations far above those reached in people.
  • Competing explanation: Low-hyperforin extracts such as Ze 117 also appear effective, so hyperforin may not be the sole driver; a manufacturer-authored review proposes cell-membrane lipid effects (Merk et al., 2025).
  • Drug-clearance effects: Hyperforin activates PXR (pregnane X receptor, a sensor that switches on drug-clearing genes) (Moore et al., 2000), inducing CYP3A4 (the liver and gut enzyme that metabolizes roughly half of all drugs), CYP2C19 (an enzyme clearing drugs such as omeprazole), CYP2C9 (an enzyme clearing warfarin and some diabetes drugs) and P-glycoprotein (a pump expelling drugs from gut and brain cells).
  • Pharmacology: Hyperforin peaks about 3.5 hours after an oral dose with a half-life near 9 hours (Biber et al., 1998, a study by the manufacturer Dr. Willmar Schwabe). Hypericin has about 14% oral availability and a 43-hour half-life (pseudohypericin 25 hours) (Kerb et al., 1996). Hyperforin is cleared by liver oxidation, mainly via the CYP2C and CYP3A enzyme families (Hokkanen et al., 2011). Selectivity is low, and only hyperforin has been detected in rodent brain.

Historical Context & Evolution

  • Traditional use: The plant is named for flowering around St. John’s Day (June 24). Greek and Roman physicians, including Dioscorides and Pliny, used it for wounds, burns and nerve pain, and medieval Europe used it against “melancholy” and evil spirits.
  • Modern medical use: Germany’s Commission E (the national expert panel on herbal medicines) approved hypericum extracts for depressive mood in 1984, and standardized extracts became widely prescribed by German physicians.
  • Route to health optimization: A 1996 meta-analysis of 23 trials reported benefit over placebo with fewer side effects than standard antidepressants, fueling a US supplement boom among people seeking a natural option for mood and stress.
  • Actual findings of the later research: Two large US trials found no advantage over placebo in moderately severe major depression: Shelton et al., 2001, funded by Pfizer, maker of the competing antidepressant sertraline, and the Hypericum Depression Trial Study Group, 2002, funded by the US National Institutes of Health, in which sertraline also failed to beat placebo. Around the same time, reduced indinavir levels and heart-transplant rejection revealed potent drug interactions.
  • Current standing: The 2008 Cochrane update found benefit but noted that trials from German-speaking countries, often manufacturer-sponsored, reported larger effects. The debate remains open: newer meta-analyses stay favorable, while independent trials in severe and minor depression remain negative.

Expected Benefits

High 🟩 🟩 🟩

Relief of Mild-to-Moderate Depressive Symptoms ⚠️ Conflicted

Standardized extracts beat placebo and matched standard antidepressants in a Cochrane meta-analysis of 29 trials and a review of 35 trials, and lowered relapse in a 26-week continuation trial sponsored by the manufacturer Schwabe. Two US trials in moderately severe depression found no benefit (Shelton et al., 2001; Hypericum Depression Trial, 2002), and German-speaking trials report larger effects. Net reading: a modest, real benefit in mild-to-moderate depression, weaker or absent in more severe illness.

Magnitude: Response rate ratio (RR, the chance of responding relative to placebo) 1.28 (95% confidence interval [CI, the range likely to contain the true effect] 1.10–1.49) in larger placebo trials; RR 1.00 versus SSRIs; relapse 18.1% versus 25.7% on placebo over 26 weeks.

Relief of Somatoform Symptoms

Somatoform disorders (persistent physical complaints such as pain, fatigue or palpitations without an identifiable medical cause) improved in two placebo-controlled trials of 600 mg/day in outpatients without major depression (Volz et al., 2002; Müller et al., 2004). Tolerability matched placebo. Both trials tested the same commercial extract (LI 160) and were co-authored by staff of its maker, Lichtwer Pharma, so results may not transfer to other products, and no independent replication exists.

Magnitude: Responders 45.4% versus 20.9% on placebo after 6 weeks (Müller et al., 2004).

Medium 🟩 🟩

Reduction of Menopausal Hot Flashes ⚠️ Conflicted

A meta-analysis found hypericum preparations superior to placebo for menopausal complaints, but several pooled trials combined it with black cohosh. Among trials of St. John’s wort alone, a 100-woman randomized trial reduced hot-flash frequency, severity and duration over 8 weeks, while a 47-woman pilot trial found no significant hot-flash change but better menopause-specific quality of life and sleep. Net reading: a plausible benefit for hot flashes and quality of life, resting on small trials.

Magnitude: Standardized mean difference (SMD, the effect size in standard-deviation units) −1.08 (95% CI −1.38 to −0.77) versus placebo, including combination products.

Premenstrual Physical and Behavioral Symptoms

In a double-blind crossover trial of 36 women, 900 mg/day for two cycles improved physical and behavioral premenstrual symptoms such as bloating and food cravings, but not mood or pain. Hormone and inflammatory-marker levels did not change. Relevance is limited to women who still menstruate.

Magnitude: Physical and behavioral symptom scores improved significantly versus placebo over two treated cycles; the trial reports no effect-size figure.

Low 🟩

Short-Term Memory and Mood in Healthy Adults ⚠️ Conflicted

In a single-dose trial in 82 students, 250 mg improved digit-span memory (repeating number sequences) while 500 mg worsened it; both doses lifted mood. A rat study is supportive (Trofimiuk et al., 2005). Net reading: an inconsistent, dose-dependent signal from one small acute study.

Magnitude: Cohen’s d (a standardized effect size) +0.58 at 250 mg and −0.48 at 500 mg for digit span; mood d 0.60.

Smoking Cessation Support ⚠️ Conflicted

Uncontrolled pilot studies suggested help with quitting, but a placebo-controlled trial of 118 smokers and a review of four randomized trials found no benefit over placebo. Net reading: no demonstrated benefit.

Magnitude: Prolonged abstinence 8.5% versus 12.5% on placebo at four weeks (odds ratio [OR, the relative odds] 0.65, 95% CI 0.22–1.92) and 4.2% versus 8.3% at six months in one trial summarized by the review; abstinence at 12 and 24 weeks did not differ from placebo in the 118-smoker trial.

Speculative 🟨

Protection Against Alzheimer’s-Type Brain Changes

In transgenic mice, dietary extract reduced brain amyloid (the protein plaque of Alzheimer’s disease) and raised a clearance pump (Brenn et al., 2014). No human outcome data exist; the basis is animal only.

Lifespan Extension

The only lifespan study found, in heat-stressed worms, showed no extension and shorter life at the highest dose (Kılıçgün & Göksen, 2012). No mammalian or human lifespan data exist.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant predicts mood response. CYP2C19 genotype changes how strongly the herb speeds clearance of other drugs (Wang et al., 2004), which shifts interaction burden rather than benefit.
  • Baseline severity: Benefit is clearest in mild-to-moderate depression. Trials enrolling moderately severe cases and minor depression found no advantage over placebo, so baseline symptom scores shape expected benefit.
  • Baseline biomarkers: No blood biomarker predicts response. People with elevated fasting glucose may see less net benefit because one small study linked use to reduced insulin secretion.
  • Sex: About two-thirds of depression-trial participants were women, and no consistent sex difference in response is reported. Hot-flash and premenstrual benefits are female-specific by nature.
  • Pre-existing conditions: Somatoform complaints and menopausal symptoms respond in trials. People on several prescription drugs gain less net benefit, because interactions limit safe use.
  • Age: Trials mostly enrolled adults aged 18–65. Older adults show the same enzyme induction (Gurley et al., 2005), and the medication load common after 60 narrows the group for whom the herb is practical.
  • Extract type: Benefit data apply to tested standardized extracts (WS 5570, LI 160, Ze 117); results may not transfer to unstandardized teas or products.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Reduced Effectiveness of Co-Administered Medications

Hyperforin induces CYP3A4, CYP2C19 and P-glycoprotein, speeding clearance of many drugs; in a systematic review of drug-level trials, 17 of 19 showed lower drug exposure. Documented consequences include transplant rejection on cyclosporine, falling levels of the HIV (human immunodeficiency virus) drug indinavir and breakthrough bleeding on oral contraceptives. Induction is dose-dependent: a systematic review of CYP3A trials found no significant effect from extracts below 4 mg hyperforin daily.

Magnitude: Alprazolam exposure halved and its half-life fell from 12.4 to 6.0 hours after 14 days (Markowitz et al., 2003); indinavir exposure fell 57%; breakthrough bleeding occurred in 7 of 12 versus 2 of 12 women.

Mild Gastrointestinal Upset, Headache, Dizziness and Fatigue

In a systematic review of 35 double-blind trials, side-effect and dropout rates were similar to placebo, lower than older antidepressants and slightly lower than SSRIs. Gastrointestinal upset, headache, dry mouth, dizziness and tiredness are the most commonly reported; anxiety or restlessness and sexual dysfunction occur less often (an NCCIH fact sheet). One US trial found headache more frequent than on placebo. Effects are usually mild and reversible.

Magnitude: Headache 41% versus 25% on placebo (Shelton et al., 2001); OR of dropping out for side effects 0.53 (95% CI 0.34–0.83) versus SSRIs (Linde et al., 2008).

Medium 🟥 🟥

No risk rests on a single controlled trial or on consistent observational data alone: the remaining risks come from uncontrolled before-and-after studies, case reports and small, inconclusive observational cohorts.

Low 🟥

Increased Skin Sensitivity to Sunlight

Hypericin is a light-activated skin sensitizer. In a volunteer study, 1,800 mg/day modestly increased sensitivity to UV-A (ultraviolet A, the longer-wave sunlight band), while standard doses caused no average change. A severe reaction after laser treatment is reported.

Magnitude: At 1,800 mg/day the UV-A tanning threshold fell from 9.9 to 7.8 J/cm², offset by about 21% shorter light exposure.

Serotonin Syndrome With Serotonergic Drugs

Serotonin syndrome (agitation, tremor, fever and a fast heart rate from excess serotonin) is reported when the herb is combined with SSRIs, triptans (migraine drugs) or buspirone (Bonetto et al., 2007; Dannawi, 2002). Trials of the herb alone report no cases.

Magnitude: Not quantified in available studies. Only case reports exist, so incidence cannot be estimated.

Mania, Hypomania or Psychosis in Susceptible People

Case reports describe hypomania (a milder state of elevated mood and energy) and mania, mostly with a bipolar history (Nierenberg et al., 1999; Moses & Mallinger, 2000). Psychotic relapse in schizophrenia (Lal & Iskandar, 2000) and new-onset psychosis (Ferrara et al., 2017) are also reported.

Magnitude: Not quantified in available studies. Only case reports exist, so incidence cannot be estimated.

Impaired Glucose Tolerance

In 10 healthy men, 21 days of use raised glucose during a two-hour oral glucose tolerance test by reducing insulin secretion; the effect persisted six weeks after stopping. Small and uncontrolled, but relevant to long-term metabolic health.

Magnitude: Total glucose exposure and two-hour glucose rose significantly and remained higher after six weeks off; the study reports no percentage change.

Harm in Pregnancy or to Breastfed Infants

Prospective human cohorts are small: 54 exposed pregnancies showed major malformation rates similar to comparison groups, and a Danish birth cohort found a nonsignificant excess from three cases. Breastfed infants had occasional colic or drowsiness. A review of 10 rodent studies rated all methodologically weak.

Magnitude: Major malformations 5% in 54 exposed pregnancies versus 4% and 0% in comparison groups; 8.1% versus 3.3% (three cases, not significant) in the Danish cohort.

Speculative 🟨

Risk-Modifying Factors

  • Genetic polymorphisms: CYP2C19 normal metabolizers showed about 150% higher enzyme activity on the herb, poor metabolizers none (Wang et al., 2004), so interaction size with drugs like omeprazole depends on genotype.
  • Baseline biomarkers: Pre-existing high fasting glucose may compound the glucose-tolerance signal. Stable therapeutic drug levels or clotting values before starting define how much induction a person can tolerate.
  • Sex: Women using hormonal contraception or hormone therapy carry a sex-specific interaction risk. No consistent sex difference in general side effects is reported.
  • Pre-existing conditions: Bipolar disorder, psychotic disorders, organ transplantation, HIV infection, cancer chemotherapy, anticoagulation (blood-thinner treatment), and light-sensitive conditions such as lupus (an autoimmune disease) or porphyria (a rare blood-pigment disorder) sharply raise risk.
  • Age: Older volunteers showed about 140% CYP3A4 induction (Gurley et al., 2005), and five elderly patients developed serotonin syndrome when combining the herb with antidepressants.
  • Dose and extract: Extracts delivering over 10 mg hyperforin daily consistently induce CYP3A4; those under 4 mg daily did not (Whitten et al., 2006).

Key Interactions & Contraindications

Prescription drugs

  • Calcineurin inhibitors (transplant anti-rejection drugs: cyclosporine, tacrolimus): Absolute contraindication. Lower blood levels have caused acute organ rejection; if the herb was taken, stopping requires drug-level monitoring because levels rebound.
  • HIV drugs (protease inhibitors such as indinavir; non-nucleoside reverse transcriptase inhibitors such as efavirenz): Absolute contraindication. Lower drug exposure risks treatment failure and viral resistance.
  • Cancer drugs metabolized by CYP3A4 (irinotecan, imatinib, docetaxel): Absolute contraindication during treatment. Reduced exposure may cut anticancer effect.
  • Anticoagulants (blood thinners: warfarin, rivaroxaban, apixaban): Avoid or monitor closely. Faster clearance lowers anticoagulant effect and raises clot risk; INR (international normalized ratio, a clotting-time measure) checks within 1–2 weeks of starting or stopping mitigate this.
  • Hormonal contraceptives (ethinyl estradiol with norethindrone, levonorgestrel): Caution. Breakthrough bleeding and possible unintended pregnancy; backup barrier contraception during use and for 28 days after stopping mitigates risk.
  • Serotonergic antidepressants and related drugs (sertraline, fluoxetine, venlafaxine, triptans, tramadol, buspirone): Avoid combining. Risk of serotonin syndrome; a two-week gap when switching mitigates overlap.
  • Heart and cholesterol drugs (digoxin, simvastatin, verapamil, ivabradine): Caution. Lower blood levels reduce effect; digoxin levels and lipid panels 2–4 weeks after starting track this. Pravastatin is less affected than simvastatin.
  • Sedatives and opioids (alprazolam, midazolam, methadone, oxycodone): Caution. Reduced effect, including reported methadone withdrawal; dose review and symptom monitoring mitigate this.
  • Sulfonylureas (insulin-releasing diabetes drugs: gliclazide, glipizide): Monitor. Faster gliclazide clearance may weaken glucose control; home glucose checks for 2–4 weeks help.

Over-the-counter medications

  • Proton pump inhibitors (stomach-acid reducers: omeprazole, esomeprazole): Monitor. Lower drug levels may reduce symptom control, most in CYP2C19 normal metabolizers; tracking symptoms and a prescriber dose review mitigate this.
  • Dextromethorphan (cough suppressant) and other serotonergic cold remedies: Caution. Additive serotonin effects; choosing non-serotonergic cough remedies avoids overlap.
  • Fexofenadine and loperamide (drugs moved out of cells by the P-glycoprotein pump): Monitor. Long-term use lowers fexofenadine levels and may reduce allergy relief; tracking symptom relief and a dose review mitigate this.

Supplements

  • Serotonergic supplements with additive effects (5-HTP [5-hydroxytryptophan, a serotonin building block], L-tryptophan, SAMe [S-adenosylmethionine, a mood-support compound], saffron): Caution. Additive serotonin and antidepressant effects may raise serotonin syndrome risk; avoiding the combination or using low doses mitigates this.
  • Photosensitizing botanicals (psoralen-containing products such as bergamot oil and dong quai): Caution. Additive light sensitivity; sun protection mitigates.
  • Red yeast rice (contains monacolin K, identical to lovastatin, a CYP3A4-cleared statin (cholesterol-lowering drug)): Monitor. Likely loss of cholesterol-lowering effect; a lipid panel 4–8 weeks after starting tracks this.

Other interventions

  • Light-based procedures (laser resurfacing, photodynamic therapy, ultraviolet phototherapy, bright-light therapy): Caution. Risk of exaggerated burns; pausing the herb two weeks beforehand mitigates.
  • Surgery and anesthesia: Caution. Altered anesthetic drug levels (midazolam, fentanyl); stopping two weeks before elective surgery is common practice.
  • Tyramine-rich foods (tyramine, a food-derived compound that can raise blood pressure; aged cheese, cured meats, draft beer): Monitor. Isolated reports of blood-pressure spikes, such as one hypertensive crisis; evidence is weak. Limiting large servings and checking blood pressure if headache or palpitations occur mitigate this.

Populations who should avoid St. John’s Wort:

  • Organ transplant recipients taking cyclosporine, tacrolimus or sirolimus
  • People with HIV taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors
  • People receiving chemotherapy or targeted cancer drugs metabolized by CYP3A4
  • People with bipolar I or II disorder, or any past episode of mania or hypomania
  • People with schizophrenia or another psychotic disorder
  • People with severe depression (PHQ-9 [Patient Health Questionnaire-9, a nine-item depression self-rating] score of 20 or more), psychotic features or active suicidal thoughts, where trials show no reliable benefit
  • Pregnant or breastfeeding women (insufficient human safety data)
  • People with light-sensitivity disorders (porphyria, cutaneous lupus) or within two weeks of planned photodynamic or laser treatment
  • People within two weeks of elective surgery

Risk Mitigation Strategies

  • Medication review before starting: A pharmacist review of every prescription and over-the-counter drug against lists of drugs cleared by CYP3A4, CYP2C19 or the P-glycoprotein pump prevents loss of drug effectiveness from induction.
  • Low-hyperforin extract when interactions matter: Extracts delivering under 4 mg hyperforin daily (e.g., Ze 117, Zahner et al., 2019, a manufacturer study) showed no clinically relevant enzyme induction, reducing drug-interaction risk.
  • Drug-level checks at start and stop: For narrow-margin drugs, levels or INR at baseline, 2 weeks after starting and 2 weeks after stopping prevent under-dosing during induction and toxicity as induction fades.
  • Backup contraception: Barrier methods during use and for 28 days after stopping prevent unintended pregnancy from reduced contraceptive hormone levels.
  • Two-week washout: Stopping the herb 14 days before starting serotonergic drugs, elective surgery or light-based procedures prevents serotonin syndrome, anesthetic interactions and phototoxic burns.
  • Sun protection at higher doses: Broad-spectrum sunscreen with a sun protection factor of 30 or more and avoiding tanning beds at doses of 1,200 mg/day or more limit light-sensitivity reactions.
  • Mood-switch screening: Screening for past mania or hypomania before starting, and stopping at signs of reduced sleep need or racing thoughts, limits the risk of triggering mania.
  • Glucose tracking: Fasting glucose and HbA1c (glycated hemoglobin, a three-month average of blood sugar) at baseline and after 3 months detect the possible glucose-tolerance effect.

Therapeutic Protocol

  • Standard extract regimen: 300 mg three times daily (900 mg/day) of an extract standardized to 0.3% hypericin and/or 1–3% hyperforin, the regimen of most positive trials; the studied range is 600–1,800 mg/day.
  • Low-hyperforin regimen: The Ze 117 extract, developed by the Swiss manufacturer Max Zeller Söhne, is taken at about 500 mg/day; it trades a narrower efficacy literature for a much smaller interaction profile.
  • Somatoform and menopausal regimens: Somatoform trials used 300 mg twice daily of LI 160; menopause and premenstrual trials used about 900 mg/day for 8 weeks or two cycles.
  • Competing approaches: German phytotherapy practice, shaped by Commission E, treats standardized extracts as a first option for mild-to-moderate depression; conventional US psychiatry favors prescription antidepressants; integrative practitioners such as Chris Kresser present the herb as a drug-free alternative.
  • Time of day: Trials divided doses across morning, midday and evening with meals. No trial compared timing; meals reduce gastrointestinal upset, and a sleep study in older volunteers found more deep sleep.
  • Half-life: Hyperforin has a half-life of about 9 hours, hypericin about 43 hours and pseudohypericin about 25 hours; steady state is reached within about a week, while enzyme induction builds over 10–14 days.
  • Single versus split dosing: Most trials used split dosing, matching hyperforin’s short half-life; hyperforin absorption becomes less than proportional above about 600 mg per dose, which also favors dividing the daily amount.
  • Genetic polymorphisms: No genotype-guided dosing exists. CYP2C19 normal metabolizers taking CYP2C19-cleared drugs experience stronger interactions, which matters for drug choice rather than herb dose.
  • Sex: No sex-specific dosing is established. For women on hormonal contraception, the protocol includes backup contraception rather than a dose change.
  • Age: Trials used the same doses up to about age 65; for older adults, some practitioners begin at 300–600 mg/day because of higher medication loads.
  • Baseline biomarkers: Baseline PHQ-9 scores of about 5–14 correspond to the mild-to-moderate range in which benefit is documented.
  • Pre-existing conditions: Bipolar disorder, transplantation, HIV treatment and chemotherapy exclude use; well-controlled conditions on non-interacting drugs allow standard dosing.

Discontinuation & Cycling

  • Intended duration: Used as a course rather than lifelong: 4–12 weeks for acute symptoms, continued for about 6 months after response in the relapse-prevention trial. No data support indefinite use for longevity.
  • Withdrawal effects: No withdrawal syndrome was documented in trials. The main risk on stopping is relapse: 25.7% on placebo versus 18.1% on continued extract within 26 weeks.
  • Rebound drug levels: Enzyme induction fades over about 1–2 weeks after stopping, so levels of co-administered drugs such as cyclosporine, methadone or warfarin can rise into toxic ranges.
  • Tapering: Practitioners commonly taper over 1–2 weeks (900 to 600 to 300 mg/day) to track mood; this schedule is practice-based rather than trial-tested.
  • Cycling: No evidence shows that cycling maintains efficacy, and loss of effect (tolerance) is not reported in trials up to about 18 months.

Sourcing and Quality

  • Standardized extract: Products stating hypericin (about 0.3%) and hyperforin (1–3%, or under 4 mg/day for low-hyperforin types) content, ideally naming a tested extract such as WS 5570, LI 160 or Ze 117, match the trial evidence.
  • Variable quality: ConsumerLab found 60% of tested products short on key compounds, and Examine notes adulteration with other plants and dyes that inflate hypericin readings.
  • Third-party testing: Seals from USP (United States Pharmacopeia), NSF International or ConsumerLab indicate verified identity and content.
  • Reputable brands: Perika (WS 5570, Dr. Willmar Schwabe, sold in the US by Nature’s Way), Jarsin (LI 160) and Remotiv (Ze 117, Max Zeller Söhne) supply the extracts used in major trials.
  • Storage: Hyperforin and hypericin degrade with heat, light and humidity; capsules kept cool, dry and dark retain potency.
  • Teas and tinctures: These deliver unpredictable and usually lower doses and were not used in the controlled trials.

Practical Considerations

  • Time to effect: Mood effects typically appear after 2–4 weeks and plateau by 6–8 weeks; hot-flash reductions were seen at 4–8 weeks; enzyme induction develops within about 10–14 days.
  • Common pitfalls: Not telling prescribers about use, starting or stopping without adjusting interacting drugs, buying unstandardized products, stacking serotonergic supplements, and expecting benefit in severe depression.
  • Regulatory status: In the US it is a dietary supplement under DSHEA (Dietary Supplement Health and Education Act), not approved by the FDA (US Food and Drug Administration) for depression; in Germany standardized extracts are licensed herbal medicines.
  • Cost and accessibility: Standardized extracts cost roughly US$5–20 per month and are widely available; cost is not a barrier.
  • Payer incentives: Generic SSRIs and extracts both cost little, so no strong insurer incentive favoring either is evident; US insurers do not cover supplements, shifting cost and supervision to the individual.

Interaction with Foundational Habits

  • Sleep: Potentiating to neutral. A placebo-controlled study in older volunteers found more deep sleep without changes in sleep onset or duration, and perimenopausal women reported fewer sleep problems. Some people notice restlessness, so the last dose is often taken by mid-afternoon.
  • Nutrition: Indirect. Taking doses with meals reduces gastrointestinal upset. Grapefruit juice inhibits CYP3A4 and can blunt or complicate the herb’s induction of co-administered drugs. Tyramine-rich foods carry a weak, report-based caution, and the glucose-tolerance signal makes diet quality more important.
  • Exercise: None known directly. Exercise is itself an effective mood intervention and may add to the herb’s effect, though no combined trial exists. Light sensitivity at higher doses raises sunburn risk during outdoor training; sun protection mitigates this.
  • Stress management: Potentiating in animal work: extract reduced stress-induced memory impairment in rats (Trofimiuk et al., 2005). No human trials combine it with meditation or psychotherapy, though both are standard companions in depression care.

Monitoring Protocol & Defining Success

Baseline testing before starting covers four areas: a validated mood score (PHQ-9) to define the starting point, a full medication list reviewed for interactions, fasting glucose and HbA1c because of the glucose-tolerance signal, and a liver panel as a general baseline for a liver-active herb. People on warfarin or other narrow-margin drugs add an INR or drug level, and women of reproductive age confirm their contraception plan. Screening for past mania is part of the baseline.

Ongoing monitoring follows a cadence of 2 weeks (drug levels or INR if applicable), 4 and 8 weeks (PHQ-9 response), 3 months (glucose and HbA1c), then every 6 months while use continues, plus a repeat drug-level check 2 weeks after stopping. Success is defined as at least a 50% fall in PHQ-9 score by 8 weeks without new side effects.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
PHQ-9 score Below 5 (minimal symptoms) Tracks mood response Self-rated in 2 minutes; conventional bands: 5–9 mild, 10–14 moderate; a 50% drop defines response
Fasting glucose 72–90 mg/dL Detects glucose-tolerance effect Conventional normal is under 100 mg/dL; 8–12 hour fast; pair with HbA1c
HbA1c Under 5.4% Three-month glucose average Conventional normal is under 5.7%; unaffected by time of day
ALT Under 25 U/L Baseline liver function ALT (alanine aminotransferase, a liver enzyme); conventional upper limit is about 40–55 U/L depending on lab
INR (warfarin users only) No functional target; stays within the prescriber’s therapeutic range (usually 2.0–3.0) Detects loss of anticoagulation Check within 1–2 weeks of starting and of stopping the herb
Trough levels of narrow-margin drugs No functional target; stays within the prescriber’s therapeutic range Detects enzyme induction Applies to cyclosporine, tacrolimus, digoxin and similar drugs; drawn just before the next dose

Qualitative markers:

  • Mood, motivation and enjoyment of daily activities
  • Energy and daytime fatigue
  • Sleep quality and restlessness at night
  • Hot-flash frequency and severity (daily diary, for menopausal women)
  • Skin reactions after sun exposure
  • Signs of mood elevation: reduced sleep need, racing thoughts, irritability
  • Breakthrough bleeding in women on hormonal contraception

Emerging Research

  • Hyperforin analogs without interactions: El Hamdaoui et al., 2022 created Hyp13, a hyperforin-like compound that activates TRPC6 with antidepressant effects in mice but does not activate PXR. If it reaches human trials, it could separate the mood benefit from interaction risk.
  • Low-hyperforin extracts: Zahner et al., 2019, a manufacturer-sponsored study of 20 volunteers given several test drugs together (NCT03482817), found no relevant enzyme effects for Ze 117. Independent replication could strengthen the case for interaction-light products.
  • Unpublished relapse-prevention trial: A 398-patient phase 3 trial of hypericum extract for relapse prevention in moderate depression (NCT04315597), sponsored by Bayer and Steigerwald, makers of the tested extract Laif 900, was completed in 2011; its full publication could strengthen or weaken the maintenance evidence.
  • Negative signals needing replication: The glucose-tolerance study (Stage et al., 2016) and the minor-depression trial (Rapaport et al., 2011) weaken the case; larger controlled studies of metabolic effects in middle-aged adults could confirm or refute these concerns.
  • Alzheimer’s models: El Menuawy et al., 2024 reported that an apolar (fat-soluble) extract cut soluble and insoluble brain amyloid by about a quarter in mice; human cognitive trials are still absent.
  • Topical oil trials: A 110-participant trial of topical oil after nose surgery (NCT07448051) and an 80-participant cesarean wound-healing trial (NCT07012278) test skin applications that avoid the oral interaction profile.

Conclusion

St. John’s wort is a traditional European herb whose standardized extracts have been tested more thoroughly than almost any other plant remedy for mood. For proactive adults, the strongest evidence supports modest relief of mild-to-moderate low mood, with side effects that are usually milder than those of prescription antidepressants. Controlled trials also support relief of persistent unexplained physical symptoms, while smaller studies point to help with hot flashes and premenstrual complaints. Claims about memory, brain protection or longer life rest on weak or animal data.

The central trade-off is that the main active compound makes the liver and gut clear many medications faster. For someone taking transplant medications, clot-preventing medications, hormonal contraceptives, medications for viral infections or cancer, or other antidepressants, this can undo the benefit of those drugs or cause dangerous reactions. Light sensitivity, mood swings in people prone to bipolar illness, and a possible effect on blood sugar add further caution.

The evidence base is large but uneven. Many favorable trials were paid for by extract makers, and some reviewed sources come from companies that sell the herb, while independent trials in more severe or very mild depression found no benefit. Product quality varies widely, so results apply mainly to the specific extracts studied. For a health-focused adult on few or no interacting medications and with mild low mood, the herb offers a documented but modest effect whose value depends on careful attention to everything else being taken.

Top - Benefits - Risks - Protocol